Ascendis Pharma A/S - ADR (ASND)

Historical Holders from Q1 2015 to Q3 2025

Symbol
ASND on Nasdaq
Type / Class
Equity / ADR
Shares outstanding
55.6M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
63.8M
Holdings value
$12.7B
% of all portfolios
0.023%
Grand Portfolio weight change
+0%
Number of holders
275
Number of buys
153
Number of sells
-114
Average Value change %
0%
Average buys %
+0.005%
Average sells %
-0.006%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Ascendis Pharma A/S - ADR (ASND)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WESTFIELD CAPITAL MANAGEMENT CO LP 9.18% $887M 5.53M Westfield Capital Management Company, L.P. 31 Dec 2024
FMR LLC 8% $746M 4.65M FMR LLC 31 Mar 2025
JANUS HENDERSON GROUP PLC 7.8% -2.5% $859M -$20.8M 4.32M -2.37% JANUS HENDERSON GROUP PLC 30 Sep 2025
Capital International Investors 5.6% $549M 3.11M Capital International Investors 30 Jun 2025
T. Rowe Price Investment Management, Inc. 4.8% -26.7% $530M -$182M 2.67M -25.6% T. Rowe Price Investment Management, Inc. 30 Sep 2025

Institutional Holders of Ascendis Pharma A/S - ADR (ASND)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 63.8M $12.7B +$232M $198.81 275
2025 Q2 62.9M $10.9B -$374M $172.60 245
2025 Q1 65.2M $10.1B +$223M $155.86 241
2024 Q4 63.8M $8.78B +$116M $137.67 212
2024 Q3 62.6M $9.31B +$237M $149.31 218
2024 Q2 60.7M $8.28B -$25.6M $136.38 202
2024 Q1 60.8M $9.19B +$198M $151.17 188
2023 Q4 60.3M $7.59B -$95.3M $125.95 183
2023 Q3 60.3M $5.64B -$61.7M $93.64 157
2023 Q2 61M $5.45B -$42.6M $89.25 156
2023 Q1 61M $6.54B -$604M $107.22 160
2022 Q4 66M $8.05B -$66.4M $122.13 183
2022 Q3 66.7M $6.89B +$150M $103.26 177
2022 Q2 63.2M $5.88B +$99.3M $92.96 162
2022 Q1 61.9M $7.27B +$416M $117.36 169
2021 Q4 58.4M $7.85B -$60.4M $134.53 168
2021 Q3 58M $9.24B +$506M $159.39 162
2021 Q2 55M $7.24B +$278M $131.55 167
2021 Q1 52.7M $6.79B -$260M $128.88 172
2020 Q4 54.4M $9.07B +$124M $166.78 173
2020 Q3 53.5M $8.26B +$777M $154.32 150
2020 Q2 48.2M $7.13B +$39M $147.90 149
2020 Q1 47.9M $5.39B +$191M $112.61 143
2019 Q4 46.1M $6.42B -$13.7M $139.12 139
2019 Q3 46.1M $4.44B -$194M $96.32 127
2019 Q2 47.7M $5.49B +$237M $115.15 132
2019 Q1 46M $5.41B +$717M $117.70 137
2018 Q4 40.1M $2.51B -$10.8M $62.65 102
2018 Q3 40.2M $2.85B +$44.5M $70.86 94
2018 Q2 39.6M $2.63B +$96.2M $66.52 100
2018 Q1 38.1M $2.49B +$345M $65.40 89
2017 Q4 30.5M $1.22B +$50.1M $40.06 64
2017 Q3 28.8M $1.04B +$204M $36.25 59
2017 Q2 23.3M $646M +$80.3M $27.76 34
2017 Q1 20.9M $585M +$9.05M $28.00 34
2016 Q4 20.6M $416M +$131M $20.24 31
2016 Q3 14M $281M +$4.79M $20.10 22
2016 Q2 13.9M $184M +$10.2M $13.27 23
2016 Q1 12M $223M +$9.84M $18.55 25
2015 Q4 10.1M $185M +$7.68M $18.32 24
2015 Q3 8.93M $158M -$15.9K $17.70 24
2015 Q2 8.95M $158M +$7.73M $17.68 32
2015 Q1 8.48M $146M +$146M $17.35 35